COLUMBIA, Md., Jan. 31 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation (Nasdaq: MATK), a DHA omega-3 market leader, announced today that leading DHA researcher and expert Dr. Norman Salem, Jr., will be joining Martek Biosciences on February 4, 2008, as vice president and chief scientific officer.
Dr. Salem is one of the world's leading researchers on DHA and the functions of polyunsaturated fatty acids and lipids. He comes to Martek after 30 years with The National Institutes of Health where he led the internationally recognized Laboratory of Membrane Biochemistry and Biophysics. His latest scientific work focused on the role of DHA in neural development as well as how DHA is made in the body and incorporated into the brain and other organs.
As Martek's chief scientific officer, Dr. Salem will be responsible for leading clinical research, discovery, microbial biotechnology, and analytical sciences and will support the efforts of scientific affairs and medical research.
Dr. Salem received his B.S. degree in physics from Miami University and his Ph.D. in neurobiology from the University Of Rochester School Of Medicine. During his career, Dr. Salem has published over 200 research articles and book chapters. He was the 2002 recipient of the Supelco/Nicholas Pelick Research Award from the American Oil Chemists Society, which recognizes outstanding original research in fats, oils, lipid chemistry, or biochemistry. He currently serves as a research professor in the Department of Pediatrics at the F. Edward Hebert School of Medicine of Uniformed Services University of the Health Sciences.
"We are pleased to welcome Dr. Salem, a prominent expert on the science of DHA, to Martek. His scientific knowledge and experience in DHA research will provide Martek with important senior-level leadership for our clinical, scientific and research areas," said Steve Dubin, CEO of Martek Biosciences.
Martek Biosciences Corporation (Nasdaq: MATK) is a leader in the innovation and development of DHA omega-3 products that promote health and wellness through every stage of life. The company produces life'sDHA(TM), a sustainable and vegetarian source of the omega-3 fatty acid DHA (docosahexaenoic acid), for use in foods, beverages, infant formula, and supplements. The company also produces life'sARA(TM) (arachidonic acid), an omega-6 fatty acid, from a sustainable, vegetarian source, for use in infant formula. For more information on Martek Biosciences Corporation, visit http://www.martek.com. For a complete listing of life'sDHA products, visit http://www.lifesdha.com.
Sections of this release contain forward-looking statements. These
statements are based upon numerous assumptions which Martek cannot control
and involve risks and uncertainties that could cause actual results to
differ. These statements should be understood in light of the risk factors
set forth in the company's filings with the Securities and Exchange
Commission, including, but not limited to, the company's Form 10-K for the
fiscal year ended October 31, 2007 and other filed reports on Form 10-K,
Form 10-K/A, Form 10-Q and Form 8-K.
Consumer and Trade Media
|SOURCE Martek Biosciences Corporation|
Copyright©2008 PR Newswire.
All rights reserved